DECIPHERA PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.45 USD | +0.04% |
|
+0.32% | +57.78% |
| May. 10 | Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| May. 01 | North American Morning Briefing : Traders Wait for -2- | DJ |
Presenter SpeechPeter Lawson (Analysts)Thanks so much. Good afternoon. Welcome to Barclays Hea...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing new medicines to improve the lives of people with cancer. The Company is leveraging its switch-control kinase inhibitor platform in kinase biology to develop a portfolio of medicines. The Company's QINLOCK, is a switch-control kinase inhibitor, engineered using its drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor (GIST). In addition to QINLOCK, it has developed a robust pipeline of drug candidates using its switch-control kinase inhibitor platform, including vimseltinib and DCC-3116. Vimseltinib is an investigational, orally administered, potent, and highly-selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) kinase for the potential treatment of tenosynovial giant cell tumor (TGCT). DCC-3116 is a Phase 1/2 inhibitor of ULK kinases being developed to inhibit autophagy.
Calendar
2024-06-20
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
25.45
USD
Average target price
26.71
USD
Spread / Average Target
+4.96%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +57.78% | 2.2B | |
| +7.52% | 111B | |
| +11.38% | 106B | |
| -12.64% | 22.24B | |
| +0.44% | 21.25B | |
| -4.18% | 18.97B | |
| -37.85% | 18.52B | |
| -8.58% | 16.81B | |
| +37.41% | 12.54B | |
| -23.95% | 8.09B |
- Stock Market
- Equities
- DCPH Stock
- News Deciphera Pharmaceuticals, Inc.
- Transcript : Deciphera Pharmaceuticals, Inc. Presents at Barclays Global Healthcare Conference, Mar-15-2023 05